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1<ABSTRACT>
Filaggrin mutation in Korean patients with atopic dermatitis
HYE RANG ON
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Soo-Chan Kim)
Atopic dermatitis (AD) is a chronic, relapsing eczematous inflammatory 
skin disease. Filaggrin gene, FLG, mutation is a major predisposing factor for
AD. Ethnic difference exists between Asian and European populations in the 
frequencies and prevalence of FLG mutations. Also, there is a difference in 
prevalent mutations among Asian countries. The aim of this study was to
examine the spectrum of FLG mutations in Korean AD individuals; we also 
investigate the association of FLG mutations and clinical markers of AD, and 
compare the FLG landscape with other Asian countries.  
Sixty-six patients who were diagnosed as AD were enrolled in this study. 
Eleven FLG mutations previously detected in Korean, Chinese and Japanese
populations were screened by genotyping. The mean age of the patients with 
AD was 19.5 years and 71.2% were male. Four kinds of FLG null mutations 
(3321delA, S2889X, S3296X, and K4022X) were identified in total eleven 
patients (16.7%). One patient showed coexistence of two FLG mutations, 
S2889X and S3296X. There was a significant association between FLG
2mutations and allergic type of AD, palmar hyperlinearity, and a family 
history of allergic disease.
Of these mutations, three mutations (K4022X, S2889X, and S3296X) were 
first identified in Korean AD populations. In conclusion, our study expanded
the landscape FLG mutations in Korean AD population.
---------------------------------------------------------------------------------------------
Key Words : Filaggrin, Atopic dermatitis, Korean
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Ⅰ. Introduction 
Atopic dermatitis (AD), also known as atopic eczema, is a chronic and relapsing 
pruritic inflammatory skin disease, often associated with elevated serum IgE levels 
and a family history of AD, allergic rhinitis, and/or asthma.1 The prevalence of AD 
have been increased in industrialized countries during the past three decades; 15 to 
30% of children and 2 to 10% of adults.2 The various observations of the disease 
indicate that AD has a complex etiology with genetic, immunological, and 
environmental aspects. Among them, mutation of the filaggrin (FLG) gene as a
major genetic predisposing factor for AD has been investigated in many studies.3-5
FLG which was a highly insoluble, histidine-rich protein that co-purified with 
keratin intermediate filament proteins in epidermal extracts was identified by 
Beverly Dale in 1977.6 The purified protein condensed and aligned keratin 
intermediate filaments in vitro and, accordingly, was named filaggrin (for filament 
4aggregating protein).7 FLG monomers have been thought to promote the 
compaction of corneocytes by contributing to keratin pattern formation in the lower 
stratum corenum (SC).3 FLG monomers are further proteolyzed into natural 
moisturizing factors (NMFs) which are necessary to maintain hydration of the upper 
SC and acidic pH of the skin surfaces.4
FLG mutation has been identified as the underlying cause of ichthyosis vulgaris8
(IV; OMIM 146700) which is characterized clinically by dry and scaly skin, palmar 
and plantar hyperlinearity, and keratosis pilaris. Furthermore, FLG mutation has 
proved to be a major predisposing factor for AD in European and Asian 
populations.9 There are differences in FLG mutations between European and Asian 
populations. R501X and 2282del4 mutations have been reported to be the most 
common FLG mutations in Europeans,5 whereas 3321delA mutation appears to be 
the most common mutation in Chinese population and S2889X in Japanese 
population.10,11
There have been a few reports about FLG mutations (3321delA, R501X, Y1767X, 
and Q1701X) in Korean populations.12-14 This study aimed to examine the spectrum 
of FLG-null mutations in Korean AD individuals, to investigate the association of 
FLG mutations and clinical markers of AD, and to compare the FLG landscape with 
other Asian countries.
5Ⅱ. Materials and methods
1. Clinical materials
Blood samples were obtained from 66 patients with AD whose parents and all four 
grandparents were recorded as ethnic Korean. The diagnosis of AD was performed 
by experienced dermatologists using the AD diagnostic criteria by Hannifin and 
Rajka.15 According to the age of onset, patients were divided into 3 groups; early 
childhood onset (< 8), late childhood onset (8-18), and adult onset (18<). AD 
disease severity was assessed by using the SCORing Atopic Dermatitis (SCORAD) 
index and the patients with AD were grouped into mild (<15 points), moderate (15-
40 points) or severe (>40 points) disease groups. Peripheral blood samples analyzed 
for total serum IgE levels and specific IgE levels for egg, milk, soybean, peanut, 
fish, wheat, mite (Dermatophagoides pteronyssinus, Dermatophagoides farina), 
house dust, and coakroach by MAST-CLA (AdvanSureTM AlloStation, LG Life 
Science, Seoul, Korea). Total IgE concentrations ≥ 250 KIU/L and/or ≥ 3+ in 3 
categories of MAST-CLA test were considered to be allergic type of AD. Patients 
gave written informed consent, which complies with all the Declarations of Helsinki 
Principles. This study was approved by the Institutional Review Board of Gangnam 
Severance Hospital, Seoul.
2. Mutation analysis
A. DNA samples
Genomic DNA was extracted from peripheral blood lymphocytes of patients using 
a DNA extraction kit (QIAamp DNA Blood Midi kit, Qiagen, Hilden, Germany).
B. Polymerase chain reaction (PCR) amplification
Gnomic DNA was used as templates for amplication of gnomic sequences of FLG
6(GenBank NM_002016.1). Mutations R501X, 3321delA, S1695X, Q1701X, 
Q1745X, Y1767X, Q1790X, S2554X, S2889X, S3296X, and K4022X were 
amplified by PCR using pairs of oligonucleotide primers. PCR primers were 
described previously and were shown in Table1.10,16,17 Amplification conditions 
were: 95°C for 10 min, followed by 35 cycles of 95°C for 30 s, 63°C for 30 s, and 
72°C for 50s. The final extension was at 72°C for 7 min.
Table 1. The sequences of PCR primers
FLG exon3 repeats Primer pairs
1-3 5’ GCT GAT AAT GTG ATT CTG TCT G 3’
5’ GAC CCC GAT GAT TGT TCC TGT 3’
3-5 5’ GCA AGC AGA CAA ACT CGT AAG 3’
5’ ACA TCA GAC CTT TCC TGG GAC 3’
4-7 5’ GAC AAG ATT CAT CTG TAG TCG 3’
5’ CTG GCT AAA ACT GGA TCC CCA 3’
7-8 5’ CCA CAC GTG GCC GGT CAG CA 3’
5’ CTA CCG AAT GCT CGT GGT GGT 3’
7-10 5’ CCC AGG ACA AGC AGG AAC T 3’
5’ GCT TCA TGG TGA TGC GAC CA 3’
9-10 5’ GAA ACG TCT GGA CAT TCA GGA 3’
5’ GCT TCA TGG TGA TGC GAC CA 3’
10 5’ GCC CAT GGG CGG ACC AGG A 3’
5’ CTG CAC TAC CAT AGC TGC C 3’
FLG end 5’ CTA GTA CCG CTA AGG AAC ATG G 3’
5’ TGG CTC CTT CGA TAT TTC TGA 3’
7C. DNA sequence analysis
Sequence analyses were performed using Big Dye terminator technology (ABI 
3100 Perkin-Elmer, Warrington, UK).
3. Statistical analysis
Descriptive statistics for quantitative values were expressed as mean (±SD) in 
accordance with the data distribution. Frequencies and percentages were used to 
describe the categorical variable data. The statistical significance of differences in 
genotype frequency among analyzed groups was assessed using Fisher’s exact test. 
The strength of association was estimated by calculating the odds ratio (OR) with a 
95% confidence interval (CI). The level of statistical significance was established at 
α < 0.05. Statistical analyses were performed by using SPSS version 19. 
8Ⅲ. RESULTS
1. Clinical features of the AD patients
The clinical characteristics of the patients with AD are presented in Table 1 and 
Figure 1. Total sixty-six patients were enrolled in this study. Mean age of the 
patients were 19.5 years old (range 0 to 60, SD = 33.44) and 71.2% of the AD 
patients were male. AD patients showed various clinical features (Figure 1.). When 
AD severity was determined by generating objective SCORAD index, thirteen, 
twenty-three, and thirty of the patients with AD were found to have mild, moderate 
and severe disease, respectively. Fity-three (80.3%) of total patients presented 
moderate to severe SCORAD index. Total sixty-one patients (92.42%) were child-
onset AD. Twenty-six patients (39.39%) had a family history of AD. Forty-one 
(61.22%) patients showed high IgE level. In this AD cohort, 24.2% of patients 
showed hyperlinear palm. 
9Figure 1. Clinical features of patients with atopic dermatitis. Erythematous scaly 
and lichenified patches on the trunk and extremities.
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Table 2. Clinical characteristics of patients with atopic dermatitis
Characteristics Number of patients (%)
Total AD patients 66 (100%)
Mean age 20 (range 0-63)
Sex
Males 47 (71.2%)
Females 19 (28.8%)
Allergic AD* 31 (47.0%)
Hyperlinear palm 16 (24.2%)
Age of onset (year)
Early childhood (< 8) 52 (78.8%)
Late childhood (8-18) 7 (10.6%)
Adult (18<) 7 (10.6%)
Family history 26 (39.4%)
Allergic disease association 23 (34.8%)
Severity (SCORAD index)
Mild (<15 points) 13 (19.7%)
Moderate (15-40 points) 23 (34.8%)
Severe (>40 points) 30 (45.5%)
* Total IgE≥250 and/or Specific IgE ≥ 3+
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2. Identifications of FLG mutations in AD patients 
Among screened eleven mutations, four FLG mutations, S2889X, S3296X, 
3321delA, and K4022X, were identified in AD patients (Table 2 and Figure 2). 
Total eleven patients were detected with FLG mutations and were all heterozygous 
for those mutations. All patients with FLG mutations showed moderate to severe 
clinical features of AD (Figure 3). Mutations S2889X, S3296X, 3321delA, and 
K4022X were found to be carried by 1 (1.5%), 2 (3.0%), 6 (9.1%), and 3 (4.5%) 
individuals. One patient was a heterozygous carrier of two different FLG mutations. 
Identification of S2889X, S3296X, and K4022X in this study is the first 
identification in Korean AD populations (Figure 4).
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Figure 2. FLG mutations detected in patients with atopic dermatitis (A) 
Heterozygous deletion mutation in FLG repeat 2 in exon3 in patient no.28, 
3321delA was identified. (B) Two heterozygous transition mutations c.8666C à G 
and c.8667C à A in patient no.11, resulting in S2889X. (C) A heterozygous 
transition mutation c.9887C à A in patient no.66, resulting in S3296X. (D) A 
heterozygous transition mutation 14011A à T in patient no.40, resulting in 
nonsense mutation K4022X
Table 3. Atopic dermatitis association analysis for FLG null variants in Korea
R501X 3321delA Y1767X S1695X Q1701X Q1745X Q1790X S2554X S2889X S3296X K4022X
Genotype
AA 66 60 66 66 66 66 66 66 65 64 63
Aa 0 6 0 0 0 0 0 0 1 2 3
aa 0 0 0 0 0 0 0 0 0 0 0
Total 66 66 66 66 66 66 66 66 66 66 66
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Figure 3. Clinical features of patients with atopic dermatitis (A) Palmar 
hyperlinearity of AD patient with K4022X mutation (B) Fine scales and xerosis on 
the trunk of AD patient with S2889X and S3296 mutations (C) Erythematous 
papules and patch on the back of AD patient with 3321delA mutation
Figure 4. FLG null mutations found in Korean ichthyosis vulgaris (IV) and 
atopic dermatitis (AD). In total, seven FLG-null mutations have been detected in 
Korean IV and AD. Mutations in blue color were found in Korean populations for 
the first time from this study.
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3. Associations between FLG mutations and AD chatacteristics (Table 3.)
FLG mutations were significantly associated with allergic type of AD, palmar 
hyperlinearity, and a family history of allergic disease (p < 0.05). Among AD 
patients with FLG mutations, a high percentage (90.9%) of patients showed high 
IgE level and/or positive for MAST-CLA. Palmar hyperlinearity was showed in 
eight patients (72.72%) of AD patients with FLG mutations. Eight patients (72.72%) 
had a family history of allergic disease. There was no significant association 
between onset age and FLG mutations. All patients with FLG mutations showed 
moderate to severe severity. Forty two patients (63.63%) in non-FLG mutation 
group showed moderate to severe severity. No significant association were detected
between AD severity and FLG mutations statistically (p=0.088).
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Table 4. Clinical characteristics of AD patients with and without FLG mutations
Characteristics
AD with FLG 
mutations (%)
AD without FLG 
mutations (%)
p value
Number of patients 11 (16.7) 55 (83.3) -
Age (range) 28 (0-63) 19 (0-43) -
Sex 
Males 8 (72.7) 39 (70.9) -
Females 3 (27.3) 16 (29.1) -
Allergic AD* 10 (90.9) 21 (38.1) 0.002
Hyperlinear palm 8 (72.7) 8 (14.5) <0.001
Age of onset (year) 0.626
Early childhood (< 8) 8 (72.7) 44 (80.0)
Late childhood (8-18) 1 (9.1) 6 (10.9)
Adult (18<) 2 (18.2) 5 (9.1)
Family history of allergic disease 8 (72.7) 19 (34.5) 0.040
Allergic disease association 4 (36.4) 19 (34.5) 1.000
Severity (SCORAD index) 0.088
Mild (<15 points) 0 (0) 13 (23.6)
Moderate (15-40 points) 3 (27.3) 20 (36.4)
Severe (>40 points) 8 (72.7) 22 (40.0)
* Total IgE≥250 and/or Specific IgE ≥ 3+,
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Ⅳ. Discussion
The human profilaggrin gene is located on chromosome 1q21 and consists of 3 
exons of which exon 1 is noncoding and exon 2 encodes part of the S100 domain, 
and exon 3, one of the largest exons in the genome at more than 12.7 kb, encodes 
almost the entire profilaggrin protein.4 In the final process of keratinocyte 
differentiation, profilaggrin is dephosphorylated and cleaved into 10–12 FLG
peptide units. The liberated FLG subsequently and efficiently aggregates the keratin 
filament cytoskeleton, causing the collapse of the granular cells into flattened 
residual cells.7 The collapsed cytoskeleton is crosslinked by transglutaminases to 
bind it to the cornified cell envelope.9 FLG degradation products also contribute to 
moisture retention in the cornified layers as a natural moisturizing factor (NMF).4
Thus, FLG is a key epidermal protein essential for the formation of a normal skin 
barrier. During the past few years, a strong association between FLG defects and 
allergic disorders has been observed in different populations.
Previous reports have identified FLG as the causative gene for IV but have 
highlighted that prevalence and frequency of FLG mutations in each populations are 
distinct.10,11,16,18-22 The most prevalent FLG mutations in the U.K. population are 
R501X and 2282del4 which are not commonly found mutations in Asian 
populations.20 The differences in the FLG mutation landscape between China, 
Taiwan, Singapore and Japan also exist. The two mutations S2554X and S2889X 
are the most prevalent FLG mutations in Japan,10,23 whereas mutations K4022X and 
3321delA are the most common FLG mutations in AD cohort in China.11,22 Hsu CK
et al.24 identified three FLG mutations, 3321delA, Q2417X, and E1795X, in 
Taiwanese ichthyosis vulgaris families. The 3321delA mutation was the most 
prevalent FLG mutation in Singapore.21 Only 3321delA mutation was commonly 
detected Asian countries including China, Singapore, Japan, Korea and Taiwan. 
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Thus, eleven mutations R501X, 3321delA, S1695X, Q1701X, Q1745X, Y1767X, 
Q1790X, S2554X, S2889X, S3296X, and K4022X which were reported in Korean 
and other Asian population were selected for FLG mutation analysis in the present 
study. The first clear finding from this study is that we expanded the landscape of 
FLG-null mutations in Korean AD individuals. 3321delA was detected in 6 AD 
patients (9.1%) and K4022X was detected in 3 AD patients (4.5%). Two mutations,
3321delA and K4022X, appear to be the most common FLG mutations in Korean 
AD patients from this study. This prevalence is similar to China than Japan. Though 
S2554X which was the most common FLG mutations in Japan was not detected in 
this study, S2889X (n=1) and S3296X (n=2, 3.1%) which were commonly found in 
Japanese AD patients were detected in two Korean patients. One patient who had 
two mutations S2889X and S3296X showed hyperlinear palms and clinical features 
of IV and AD with scales, erythema and severe xerosis on the whole body. K4022X, 
S2889X and S3296X have never been reported in Korean populations before. 
The frequency of FLG mutation was 31.4% and 26.0% in Chinese AD patients in 
previous reports.11,22 A Japanese AD case–control study for the eight FLG mutations 
demonstrated that about 27% of the patients in Japanese AD case series carry at 
least one FLG mutation.23 In our present FLG mutation study, the frequency (16.7%) 
of FLG mutations in Korean AD patients was higher than previous AD case-control 
study in which the frequency of FLG mutations (R501X, E2422X, and 3321delA) 
was much lower (2.6%) in Korean than other population.14 And, this frequency was 
due to that we identified more mutations than previous study. 
Palmar hyperlinearity which have been previously reported to be strong clinical
markers of FLG-null mutations was shown in 72.7% of AD patients with FLG
mutation.4,25 The significant association between palmar hyperlinearity and FLG
mutations was observed in the present study.
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Strong association between FLG mutations and AD was shown in many 
literatures.10,11,16,20-22 In this study, most patients (80.3%) had moderate to severe 
SCORAD index. Chen et al.21 reported the significant association of the FLG 
mutations with AD severity. In present study, though percentage of severe AD was 
higher in patients with FLG mutations, there was no significant association was 
observed between FLG mutations and AD severity. Many previous reports did not 
identify association of FLG mutations with disease severity.10,11,14,22 The lack of 
association with severity maybe due to the age at which SCORAD was determined 
and due to the fact that the SCORAD is a ‘‘snap shot’’ variable that does not reflect 
the overall disease activity.26 Although FLG mutation is considered as major 
predisposing factor of AD, AD is multifactorial disease which is affected by many 
other candidate genes, environmental factors like humidity and infection. 
It was shown that FLG mutations related to early onset and persistent AD with 
increased total IgE levels and allergic sensitization was also reported rather than 
SCORAD index.26,27 H. Rupnik et al.28 reported that 2282del4 mutation was 
associated with AD that developed during infancy or in had a much earlier age of 
onset than those not carrying any FLG mutations, indicating the effect of FLG 
mutations on the age of onset for AD. But, there was no significant association 
between onset age and FLG mutations in the present study. Meng et al.29 also did 
not find the association between early-onset between early-onset AD and FLG
mutation c.3321delA. There is still a controversy between early-onset AD and FLG
mutation. 
FLG mutations and allergic disease association was investigated. In our study, no 
statistical significance was observed for the association between associated allergic 
diseases and FLG mutations. However, it was shown in Japanese that there was a 
statistically significant association between the FLG mutations and asthma with 
AD.23 FLG is not expressed in the respiratory epithelia and the mechanisms of this 
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relationship are as yet unclear. One possible mechanism is skin barrier defects 
caused by FLG mutations allow antigen transfer through a defective epidermal 
barrier, resulting in initiation of further immune response and leading to the 
development of systemic allergies, including atopic asthma.30,31 If early intervention 
for the repair of the epidermal barrier is conducted in AD patients with FLG
mutations for preventing the subsequent development of the ‘atopic march’, we may 
consider the screening for FLG mutations to be a noninvasive test to predict AD
course in the clinical field. 
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Ⅴ. Conclusion
We performed FLG mutational analysis of 66 patients with atopic dermatitis.
Eleven FLG mutations were screened. Four kinds of screened FLG null 
mutations (3321delA, S2889X, S3296X, and K4022X) were identified in 
total eleven patients. Mutations 3321delA and K4022X were two of the most 
common mutations in this AD cohort. S2889X, S3296X, and K4022X were newly
identified in Korean AD populations from this study. Prevalence of FLG mutations 
in Korean AD population was 16.7%. We investigate the association of FLG
mutations and clinical markers of AD. FLG mutations were significantly 
associated with allergic type of AD, palmar hyperlinearity, and a family history of 
allergic disease.
This study expanded the landscape FLG mutations in Korean AD
population and showed the association of FLG mutations and clinical markers of 
AD.
21
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ABSTRACT(IN KOREAN)
한국인 아토피 피부염 환자에서 필라그린 유전자 변이의 확인
<지도교수 김수찬>
연세대학교 대학원 의학과
온혜랑
아토피 피부염은 만성, 재발성 염증성 피부 질환으로 필라그린 유전자의
변이가 이러한 아토피 피부염의 주된 선행 인자로 생각된다. 호발하는
필라그린 변이의 종류와 빈도는 아시아와 유럽에서 각각 다르게
나타난다. 아시아에서도, 중국과 일본에서 각각 호발하는 변이가 다르게
나타난다. 아직까지 한국에서의 호발하는 필라그린 변이에 대해서는 많은
연구가 이루어 지지 않아 본 연구에서는 한국인에서 호발하는 필라그린
변이를 확인하고, 이러한 변이와 더불어 한국인 아토피 피부염 환자들의
임상 양상을 비교하고, 아시아의 다른 국가들과 변이 여부를
비교해보고자 하였다. 
강남 세브란스 병원 피부과 외래에 내원하여 아토피 피부염으로 진단
받은 총 66명의 환자를 대상으로 하였고, 그 동안 한국인과 일본 및
중국에서 보고된 필라그린 변이를 확인하였다.
환자들의 평균 나이는 19.5살이었으며 71.2%가 남성이었다. 총
11명의 환자에서 4종류의 필라그린 변이(3321delA, S2889X, S3296X, 
K4022X)가 확인되었다. 한 명의 환자는 2종류의 필라그린 변이(S2889X
25
and S3296X)를 보였다. 필라그린 변이의 유무와 알레르기성 아토피
피부염, 손바닥의 많은 잔주름, 알레르기 질환의 가족력 간에 유의한
상관관계가 있었다. 그러나, 아토피 피부염의 발병 연령과 중증도는
필라그린 변이와의 유의한 상관관계가 없는 것으로 나타났다. 
또한 본 연구에서 보고된 4종류의 변이 중에서 K4022X, S2889X, 
S3296X는 한국인에서는 처음으로 보고되었다. 본 연구를 통해
한국인에서 새로운 필라그린 변이를 확인하고 아토피 피부염의 특징적인
임상 양상과 필라그린 변이의 연관성을 확인하였다. 
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